Myasthenia triggered by immune checkpoint inhibitors: New case and literature review

Neuromuscular Disorders

Volumn 27, Issue 3, 2017, Pages 266-268

  Gonzalez, Natalia L ^a   Puwanant, Araya ^a   Lu, Angela ^a   Marks, Stanley M ^b   Živković, Saša A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; HyperCKemia; Immune checkpoint inhibitor; Myasthenia gravis; Myositis

Indexed keywords

CARBOPLATIN; CREATINE KINASE; EVEROLIMUS; PACLITAXEL; PEMBROLIZUMAB; PREDNISONE; PYRIDOSTIGMINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; AGED; ARTICLE; BONE METASTASIS; CARCINOSARCOMA; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DIPLOPIA; DISEASE SEVERITY; DYSARTHRIA; DYSPHAGIA; ELECTROMYOGRAPHY; FEMALE; FLEXOR MUSCLE; HIP MUSCLE; HUMAN; LABORATORY TEST; LATERAL RECTUS MUSCLE; LUNG METASTASIS; LYMPH NODE METASTASIS; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOSITIS; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PTOSIS; SYMPTOM; TREATMENT RESPONSE; UTERUS SARCOMA; BLOOD; CHEMICALLY INDUCED; PATHOPHYSIOLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CREATINE KINASE; FEMALE; HUMANS; MYASTHENIA GRAVIS;

EID: 85009786708     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2017.01.002     Document Type: Article

References (19)

1. [1] Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
2. [2] Friedman, C.F., Proverbs-Singh, T.A., Postow, M.A., Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2 (2016), 1346–1353.
3. [3] Hottinger, A.F., Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29 (2016), 806–812.
4. [4] Zimmer, L., Goldinger, S.M., Hofmann, L., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 210–225.
5. [5] Johnson, D.B., Saranga-Perry, V., Lavin, P.J., et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 33 (2015), e122–4.
6. [6] Liao, B., Shroff, S., Kamiya-Matsuoka, C., Tummala, S., Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16 (2014), 589–593.
7. [7] Loochtan, A.I., Nickolich, M.S., Hobson-Webb, L.D., Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52 (2015), 307–308.
8. [8] Kimura, T., Fukushima, S., Miyashita, A., et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107 (2016), 1055–1058.
9. [9] Maeda, O., Yokota, K., Atsuta, N., Katsuno, M., Akiyama, M., Ando, Y., Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 78 (2016), 119–122.
10. [10] Sciacca, G., Nicoletti, A., Rampello, L., Noto, L., Parra, H.J., Zappia, M., Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 54 (2016), 507–509.
11. [11] Shirai, T., Sano, T., Kamijo, F., et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46 (2016), 86–88.
12. [12] Lau, K.H., Kumar, A., Yang, I.H., Nowak, R.J., Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 54 (2016), 157–161.
13. [13] Zhu, J., Li, Y., Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 54 (2016), 506–507.
14. [14] Rizvi, N.A., Mazieres, J., Planchard, D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265.
15. [15] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373 (2015), 23–34.
16. [16] Antonia, S., Goldberg, S.B., Balmanoukian, A., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17 (2016), 299–308.
17. [17] Sheik Ali, S., Goddard, A.L., Luke, J.J., et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151 (2015), 195–199.
18. [18] Paik, J.J., Corse, A.M., Mammen, A.L., The co-existence of myasthenia gravis in patients with myositis: a case series. Semin Arthritis Rheum 43 (2014), 792–796.
19. [19] Berrih-Aknin, S., Le Panse, R., Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52 (2014), 90–100.